We interviewed a US-based neurologist who specializes in Alzheimer’s disease (AD) treatment to gauge his views on drugs in clinical development for AD, including anti-beta amyloid monoclonal antibodies (mAbs) from Biogen and Roche, beta secretase (BACE) inhibitors from AstraZeneca, Johnson & Johnson and Merck, selective 5-HT6 receptor antagonists from Axovant and Suven and a receptor for advanced glycation end products (RAGE) antagonist from vTv Therapeutics. The specific drugs discussed include aducanumab (BIIB), AVP-786, AZD3293 (AZN), azeliragon (VTVT), crenezumab (RHHBF), gantenerumab (RHHBF), intepirdine (AXON), JNJ-54861911 (JNJ), SUVN-502 and verubecestat (MRK).

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.

For our disclosures, please read the Biomedtracker Research Standards.